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16 Antibodies are routinely used as research tools, in diagnostic assays and increasingly as
17 therapeutics. Ideally, these applications require antibodies with high sensitivity and speciﬁcity;
18 however, many commercially available antibodies are limited in their use as they cross-react
19 with non-related proteins. Here we describe a novel method to characterize antibody
20 speciﬁcity. Six commercially available monoclonal and polyclonal antibodies were screened
21 on high-density protein arrays comprising of ~10,000 recombinant human proteins (Imagenes).
22 Two of the six antibodies examined; anti-pICln and anti-GAPDH, bound exclusively to their
23 target antigen and showed no cross-reactivity with non-related proteins. However, four of the
24 antibodies, anti-HSP90, anti-HSA, anti-bFGF and anti-Ro52, showed strong cross-reactivity
25 with other proteins on the array. Antibody–antigen interactions were readily conﬁrmed using
26 Western immunoblotting. In addition, the redundant nature of the protein array used, enabled
27 us to deﬁne the epitopic regionwithin HSP90 of the anti-HSP90 antibody, and identify possible
28 shared epitopes in cross-reacting proteins.
29 In conclusion, high-density protein array technology is a fast and effective means for
30 determining the speciﬁcity of antibodies and can be used to further improve the accuracy of
31 antibody applications.
32 © 2008 Published by Elsevier B.V.
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41
42 1. Introduction
43 Since antibodies possess unique antigen binding sites,
44 which can discriminate between millions of different anti-
45 gens, their speciﬁcity is the basis for their use in many
46 applications. Antibodies are routinely used as tools in teasing
47 apart molecular pathways in techniques such as Western
48 immunoblotting and ELISA. The diagnosis of disease and
49 targeted therapies are increasingly becoming more depen-
50dent upon antibodies (Waldmann and Morris, 2006). More
51recently, antibody arrays, containing hundreds or thousands
52of antibodies, have been shown to be invaluable in protein
53proﬁling (Barry and Soloviev, 2004). To exploit the full
54potential of these applications, antibodies with high speciﬁ-
55city are required and potential cross-reactivities need to be
56identiﬁed. Although commercial antibodies are widely used
57within the research ﬁeld, many lack the speciﬁcity required to
58be used as reliable tools mainly because there are few robust
59methods available to assess non-speciﬁc binding.
60New developments in immunology are implementing
61array technology to assess antibody function (Murphy and
62Cahill, 2005). Peptide arrays, random peptide libraries
63(Reineke et al., 2002; Poetz et al., 2005; Yu et al., 2006;
64Paley et al., 2007) multiplexed bead approaches (Warren and
65Bettadapura, 2005; Schwenk et al., 2007) are increasingly
66being used to identify the interactions of antibodies. While
67often highly successful, these methods are limited by the low
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68 number of potential antigens or require lengthy experimental
69 procedures. Protein microarrays containing hundreds of
70 proteins have been successfully applied to examine speciﬁcity
71 and cross-reactivity of custom-made antibodies to yeast
72 (Michaud et al., 2003) and human liver proteins (Hu et al.,
73 2007). Several studies have demonstrated the potential of
74 protein arrays in the identiﬁcation of antigen–antibody
75 interactions for human proteins (Bussow et al., 1998; Holt
76 et al., 2000). The large protein arrays used represent a
77 powerful alternative approach for identifying potential cross-
78 reactivities in a high-throughput format, as more than 10,000
79 recombinant human proteins can be simultaneously ana-
80 lyzed. In addition, the sequence information for each
81 expressed protein is available (Imagenes), allowing rapid
82 identiﬁcation of binding interactions.
83 In this study, we describe a rapid approach to deﬁne the
84 molecular targets for various commercial monoclonal and
85 polyclonal antibodies using high-density protein arrays. We
86 screened six antibodies commonly used in different ﬁelds of
87 research to determine possible binding interactions on the
88 protein array. Our results conﬁrm that some monoclonal
89 antibodies are mono-speciﬁc, however others show strong
90 cross-reactivity. Since the sequence information is available
91 for all cross-reacting proteins, we were able to map epitopic
92 regions shared between these antigens. In conclusion, high-
93 density protein arrays are a powerful high-throughput
94 technique to determine cross-reactivity of antibodies which
95 may help to assess the quality of newly produced antibodies
96 and conﬁrm the speciﬁcity of antibodies already in use.
97 2. Materials and methods
98 2.1. Protein arrays
99 The high-density protein arrays used in this study contain
100 38,016 Escherichia coli expression clones from a human foetal
101 brain cDNA (hEx1) library arrayed on PVDF membranes
102 (Imagenes, GmbH). The expression clones were generated in
103 the expression vector pQE30NST (GenBank Accession No.
104 AF074376) and were transformed into E. coli strain SCS1
105 (Stratagene) (Bussow et al., 1998; Horn et al., 2006). Sequence
106 information for individual clones recognized by antibodies
107 was provided by Imagenes GmbH.
108 2.2. Antibody screening
109 Prior to antibody screening, the dried colonies were
110 removed from the PVDF membranes with tissue paper and
111 TBSTT (TBS supplemented with 0.05% Tween 20 and 0.5%
112 TritonX-100). Followed by three washes, for 20 min each, in
113 TBST (TBS supplemented with 0.05% Tween 20) and blocking
114 with 3% (w/v) skimmed milk powder (Marvel) in TBST for 3 h
115 at room temperature, the membranes were incubated over-
116 night with one of the following primary antibodies: anti-
117 HSP90 monoclonal antibody, (sc-13119; Santa Cruz Biotech-
118 nology); anti-GAPDH monoclonal antibody (Clone 6C5;
119 Research Diagnostics); monoclonal anti-HSA (Clone 1C8,
120 Hytest), monoclonal anti-pICln (Clone 32; BD Biosciences);
121 monoclonal anti-basic Fibroblast Growth Factor (bFGF),
122 (Clone FB-8; Sigma); polyclonal anti-Ro52 (sc-20960, Santa
123 Cruz Biotechnology). All antibodies utilised in this study are
124human speciﬁc and were used at dilution (1/1000, in 2% BSA/
125TBST) recommended by the manufacturer. Primary antibody
126incubation was followed by three washes of 20 min each in
127TBST. The protein arrays were then incubated with the
128secondary antibody conjugated with alkaline phosphatase
129(AP); anti-mouse IgG (A1418; Sigma,) or anti-rabbit IgG (111-
130055-045; Jackson ImmunoResearch) appropriate to each
131primary antibody for 1.5 h. Following three washes for
13220 min each in TBST, the membranes were incubated for
13310min in AP buffer (1mMMgCl2,100mMTris–Cl, pH 9.5) and
1345 min in 0.125 mM Attophos in AP buffer. Filters were
135illuminatedwith long-wave UV light (460 nm EPI) and images
136were taken using a high resolution CCD camera (Fuji
137LAS3000). Image analysis was performed using VisualGrid
138(GPC Biotech). In order to eliminate any background binding,
139each secondary antibody used for detection was additionally
140screened against the arrays in the absence of the primary
141antibody and all expression clones detected were removed
142from the list generated for the primary antibody. The
143identities of clones bound by tested primary antibodies
144were obtained from Imagenes GmbH and conﬁrmed by
145sequencing.
1462.3. Recombinant protein expression and puriﬁcation
147The E. coli clones expressing the recombinant HIS-tagged
148proteins from the hEx1 library were purchased from
149Imagenes GmbH. Clones were grown in 5 ml liquid cultures
150and protein expression induced with 1mM IPTG and puriﬁed
151as previously described using nickel afﬁnity chromatography
152(Bussow et al., 1998; Lueking et al., 1999). The size of each
153puriﬁed protein was determined by SDS PAGE using Coo-
154massie staining and Western immunoblotting using a mouse
155anti-RGS–His antibody (34650, Qiagen).
1562.4. Western immunoblotting
157The puriﬁed proteins were separated by SDS PAGE and
158transferred onto PVDF membranes at 100 V for 1 1/2 h. The
159membrane was blocked for 2 h in 3% Marvel/TBST, washed in
160TBS (3×10 min) and incubated for 2 h with the primary
161antibody as described above. Antibody binding was detected
162using an alkaline phosphatase-conjugated anti-mouse, or
163anti-rabbit, IgG secondary antibody (Sigma) and visualized on
164a Fuji LAS 3000 imager.
1652.5. Epitope mapping
166Amino acid sequence alignment and deﬁnition of potential
167epitope regions were performed using the web-based soft-
168ware SIM (http://us.expasy.org/tools/sim-prot.html), LALIGN
169(http://www.ch.embnet.org/software/LALIGN_form.html)
170and CLUSTALW.
1713. Results
1723.1. Characterization of commercial antibodies
173Probing protein arrays with antibodies enables the
174assessment of speciﬁcity and cross-reactivity on large
175numbers of potential antigens in parallel. Here we
2 G. Kijanka et al. / Journal of Immunological Methods xxx (2008) xxx–xxx
ARTICLE IN PRESS
Please cite this article as: Kijanka, G., et al., Rapid characterization of binding speciﬁcity and cross-reactivity of antibodies using
recombinant human protein arrays, J. Immunol. Methods. (2008), doi:10.1016/j.jim.2008.10.008
UN
CO
RR
EC
TE
D
PR
OO
F
176 characterize the speciﬁcity and cross-reactivity of a panel of
177 commonly used commercially available antibodies. These
178 were the monoclonal antibodies: anti-HSP90, anti-HSA, anti-
179 pICln, anti-GAPDH, anti-bFGF and a polyclonal anti-Ro52
180antibody. We screened these antibodies against the hEx1
181protein arrays (Bussow et al., 1998, 2000) which contain a
182redundant set of 38,016 clones expressing recombinant
183human proteins. The antibodies characterized here and the
184corresponding antigens identiﬁed in this study are listed in
185Table 1.
1863.2. Screening protein arrays conﬁrms mono-speciﬁcity of two
187antibodies
188Two of the six antibodies tested on the protein arrays
189demonstrated mono-speciﬁcity: anti-pICln and anti-GAPDH,
190bothofwhicharemonoclonal. Theanti-GAPDHantibody (Clone
1916C5) is widely reported as being highly speciﬁc with no other
192banding in Westerns reported (e.g. (Li et al., 2004)). This
193antibody recognized 81 expression clones on the arrays, all of
194which express GAPDH protein. A representative section of the
195protein array is shown in Fig. 1a. Sequencing revealed that all
196clones express full length protein. The antibody–GAPDH
197binding was conﬁrmed using Western immunoblotting
198(Fig. 1b). The monoclonal anti-pICln (Clone 32) recognized 6
199expression clones on the hEx1 protein array (Fig. 1c). Sequen-
200cing conﬁrmed all clones expressed large fragments or full-
201length pICln. All 6 pICln clones identiﬁed in this study express a
202pICln fragment which includes the immunogenic region (92–
203201 amino acids) as reported by the manufacturer. The
204antibody–pICIn binding was conﬁrmed for all 6 clones using
205Western immunoblotting (Fig. 1d). The banding pattern in the
206Westerns matches our previously reporting that this antibody
207recognises both the full length protein and degradation
208products both in human platelet lysates and for bacterially
209expressed recombinant protein (Larkin et al., 2004). Mass
Table 1t1:1
Antibody–antigen interactions identiﬁed using high-density protein arrays
and conﬁrmed by Western immunoblotting
t1:2
t1:3 Antibody Proteins bound by antibody Acc. number
t1:4 α-GAPDH GAPDH P04406
t1:5 α-ICln Chloride channel, nucleotide sensitive 1a P54105
t1:6 α-bFGF bFGF P78443
t1:7 Pyrroline-5-carboxylate reductase 1 P32322
t1:8 Alu7 P39194
t1:9 Heterogeneous nuclear ribonucleoprotein D-like Q6SPF2
t1:10 CDC42 binding protein kinase beta NP_006026
t1:11 α-HSA Human serum albumin P02768
t1:12 Phosphatidylethanolamine-binding protein P30086
t1:13 ADP-ribosylation factor-like protein 5A. Q9Y689
t1:14 Kv channel-interacting protein 1 (KChIP1) Q9NZI2
t1:15 α-Ro52 Ro 52 NM_003141
t1:16 GPAA1P anchor attachment protein 1 NM_003801
t1:17 Zinc ﬁnger protein 6 NM_021998
t1:18 Zinc ﬁnger protein 354A NM_005649
t1:19 HLA-B associated transcript 3 NM_080702
t1:20 Triosephosphate isomerase 1 NM_000365
t1:21 Cell division cycle associated 5 NM_080668
t1:22 chromosome 10 open reading frame 104 NM_173473
t1:23 Hypothetical protein MGC2803 BC000216
t1:24 CRAMP1L , Crm, cramped-like AB037847
t1:25 Hippocalcin BC001777
t1:26 Hypothetical protein LOC51031 NM_016080
t1:27 cDNA DKFZp761G1421 AL713634
t1:28 α-HSP90 HSP90 P08238
t1:29 SH2-B gamma signalling protein AF227969
t1:30 Radixin L02320
Fig. 1. Mono-speciﬁc antibodies veriﬁed by high-density protein arrays. (a) Representative section of the protein array probed with monoclonal anti-GAPDH
antibody, all identiﬁed clones express full-length GAPDH protein. (b) Western immunoblot analysis of recombinant RGS-His tagged GAPDH conﬁrms presence of
GAPDH (α-RGS-His) and its interaction with the α-GAPDH antibody. (c) Protein array probed with monoclonal anti-ICIn antibody. (d) Six clones expressing
different ICIn fragments were identiﬁed and conﬁrmed using Western immunoblot.
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210 spectrometry has since conﬁrmed the identity of the putative
211 degradation bands as ICln (NiamhMoranandAchimTreumann,
212 personal communication). Clone C4 codes for and expresses a
213 shortened ICln protein, missing the ﬁrst 67 amino acids.
214 3.3. Protein arrays identify cross-reactivities for monoclonal and
215 polyclonal antibodies
216 Monoclonal antibodies against HSA and bFGF antibody
217 revealed a number of cross-reactivities upon screening of the
218 hEx1 protein array. We observed and conﬁrmed that anti-
219 bFGF (FB-8) cross-reacted with 4 other proteins on the array
220 and in Western immunoblots, including three clones expres-
221 sing Heterogeneous nuclear ribonucleoprotein D-like/CArG
222 binding factor as shown in Fig. 2. The antibody used has
223 previously been reported to show numerous non-FGF bands
224 in Western immunoblots of lysates from a large variety of
225 lymphoma cell lines (Krejci et al., 2003), including bands
226 matching in size the proteins detected on the protein arrays.
227 The monoclonal anti-HSA (1C8) antibody, which is recom-
228 mended for ELISA use and explicitly not recommended for
229 Western immunoblotting by the manufacturer, demonstrated
230 besides speciﬁcity to the cognate HSA antigen, cross-reactiv-
231 ity with three unrelated proteins on the protein arrays and in
232 Western immunoblot (Table 1).
233 Next, we tested a polyclonal anti-Ro52 antibody for
234 speciﬁcity. Polyclonal antibodies represent a mixture of
235 immunoglobulin molecules raised against an antigen, each
236 capable of recognizing a different epitope. It is therefore likely
237 that polyclonal antibodies have higher cross-reactivity. Using
238 protein arrays we analyzed the anti-Ro52 antibody (sc-
239 20960) raised against amino acids 141–280 of the Ro52 of
240 human origin. The screening revealed binding of the antibody
241 to 18 clones expressing 13 different proteins, including the
242 cognate Ro52 (Table 1), which was the highest number of
243 cross-reacting proteins for any antibody tested.
244 3.4. Identiﬁcation of shared epitopes between unrelated proteins
245 The monoclonal anti-HSP90 (sc-13119) antibody is shown
246 by the manufacturer to cross-react with at least two other
247 proteins when used to detect HSP90 in cell lines. The antibody
248bound 25 clones on the protein array (Fig. 3a). 22 of these
249clones express HSP90 protein and 3 clones express non-
250cognate proteins. Conﬁrmation of these interactions was
251performed via Western immunoblotting (Fig. 3b). Included in
252the Western immunoblot are the clones expressing the
253longest and shortest fragments of HSP90 detected by the
254antibody, conﬁrming that the location of the epitope is near
255the carboxyl terminal (610–725 amino acids) as reported by
256the manufacturer (Santa Cruz Biotechnology Inc.). The
257binding of the anti-HSP90 antibody to the non-cognate
258proteins SH2-B and Radixin was also conﬁrmed via Western
259immunoblotting (Fig. 3b). Sequencing of the third non-
260cognate cross-reacting clone revealed the clone to contain a
261cDNA for 2,4-dienoyl-CoA reductase. However, sequencing
262also revealed that the encoding protein is not in frame with
263the 5′ RGS-His tag. This not only makes rapid puriﬁcation of
264the encoding protein difﬁcult but also raises the strong
265possibility that the antibody is cross-reacting with the in-
266frame nonsense protein.
267In order to identify potential shared epitopes, the amino
268acid sequences of SH2-B and Radixin were subjected to
269pairwise alignment (LALIGN and SIM) against the HSP90
270epitope region sequence. One region of similarity could be
271identiﬁed as a shared epitope (Fig. 3c).
2724. Discussion
273In this paper, we demonstrate the use of protein/antigen
274arrays for the routine characterization of antibodies used in
275basic research as well as, potentially, in diagnostics. Each
276antibody can be readily screened against an appropriate
277protein expression library, in this case a human foetal brain
278library arrayed on PVDF membranes (Imagenes, GmbH).
279Unlike previous approaches to characterize antibodies,
280which could at best identify potential epitopes of a particular
281antibody, this approach identiﬁes the actual target protein. In
282addition, potential cross-reacting proteins can also be
283identiﬁed using this method, which is important information
284for assessing an antibody, particularly for in vivo studies as
285well as diagnostics or therapeutics.
286One clear advantage of this approach is that expression
287clones bound by the primary antibodies can readily be
Fig. 2. Cross reactive binding identiﬁed by high-density protein array screening. (a) Representative section of the protein array probed with monoclonal anti-bFGF
antibody, screening of the arrayswith anti-bFGF revealed the antibody binds 4 proteins other than bFGF. (b)Western immunoblot analysis with anti-bFGF antibody
conﬁrms binding to bFGF, Pyrroline-5-carboxylate reductase (P5CR1), ALU7 CDC42 binding protein kinase beta (CDC42BPB) and three clones (C1–C3) expressing
Heterogeneous nuclear ribonucleoprotein D-like/CArG binding factor (HNRPDL).
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288 retrieved from the original library and large quantities of the
289 recombinant protein produced for further experimental
290 analyses. In this case, His-tagged recombinant human
291 proteins were puriﬁed using chelate-afﬁnity chromatography
292 and western immunoblotting allowed conﬁrmation of anti-
293 body interactions observed on the array. Further, most clones
294 used in these arrays have sequence information available.
295 Such information conﬁrms the protein identity and can be
296 used to gather information on putative epitopes shared
297 between cognate antigens and non-cognate proteins showing
298 cross-reactivity with the tested antibody. In one example, the
299 anti-HSP90 antibody cross-reacted with a number of clones
300 expressing proteins of the HSP90 protein, including one clone
301 encoding only a relatively short stretch of the HSP90 C-
302 terminus. This permitted a quick identiﬁcation of a short
303 epitope region within the cognate protein.
304 The interactions of the antibody with cross-reactive
305 proteins can be deduced by alignment of the primary amino
306 acid sequences of the antigens and cross-reactive proteins.
307 However, it would not be possible to predict these interac-
308 tions a priori. The cross-reactivity between two antigens may
309 occur when an antibody recognises the same epitope in two
310 different proteins. As demonstrated in this study in the case of
311the HSP90, mapping of the epitope is possible when cross-
312reactivity occurs between two different proteins with the
313same epitope. However, no common epitopes were found
314upon amino acid sequence comparison in three of four
315investigated antibodies showing cross-reactivity with unre-
316lated proteins. Cross-reactive binding due to the ability of an
317antibody to recognise different unrelated epitopes on sepa-
318rate antigens was previously described (Berzofsky and
319Schechter, 1981; James et al., 2003). Such binding may be
320caused by discontinuous epitopes, separated by several amino
321acids not directly contributing to the antibody binding (Poetz
322et al., 2005) or multi-speciﬁc antibodies (Bhattacharjee and
323Glaudemans, 1978; Van Regenmortel, 1998) making it
324impossible to map epitopes by simple sequence comparison.
325Perhaps the most signiﬁcant potential application for
326protein array screens is during antibody production to
327determine degree of speciﬁcity and identify cross-reacting
328proteins. Such information could prove invaluable for the
329scientist in deciding which antibody is best suited for a
330particular task. This application could prove even more
331valuable in the ﬁeld of diagnostic antibodies.
332Overall, our results point towards a future central role to
333be played by protein arrays in the characterization of
Fig. 3. Protein array analysis identiﬁes shared epitopes between unrelated proteins. (a) Representative section of the protein array probed with monoclonal anti-
HSP90 antibody. Anti-HSP90 antibody recognizes 23 clones, 2 of which express a protein other than HSP90. (b) The cross-reactivities of anti-HSP90were conﬁrmed
usingWestern immunoblot of the puriﬁed recombinant protein. Lane 1: SH2-B gamma signalling protein (SH2-B); three: different HSP90 clones; Radixin. (c). Using
the redundancy of the library, we could deﬁne the region of the epitope within HSP90 and use this data to ﬁnd potential epitopes within the cross-reacting
proteins.
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334 antibodies, including their integration within the production
335 process. The protein array technology described in this study
336 combines the simplicity and speed of standard ELISA
337 procedures with the parallel assessment of thousands of
338 different human proteins for speciﬁcity and cross-reactivity
339 with the investigated antibody. With the increased avail-
340 ability of higher density microarrays containing not only
341 proteins with post-translational modiﬁcations but also other
342 potential antigenic targets such as lipids and nucleic acids, the
343 approach demonstrated in this study should become an
344 attractive option for the quick analysis of antibodies.
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